Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

Moritz Müller; Florian Posch; Dominik Kiem; Dominik Barth; Lena Horvath; Michael Stotz; Renate Schaberl-Moser; Martin Pichler; Richard Greil; Philipp J Jost; Andreas Seeber; Arno Amann; Konstantin Schlick; Armin Gerger; Jakob M Riedl

doi:10.1177/17588359211039930

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

Moritz Müller, Florian Posch, Dominik Kiem (Co-Autor/-in), Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Richard Greil (Co-Autor/-in), Philipp J Jost, Andreas Seeber, Arno Amann, Konstantin Schlick (Co-Autor/-in), Armin Gerger, Jakob M Riedl

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

1 Quellenangabe (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	17588359211039930
Fachzeitschrift	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Jahrgang	13
DOIs	https://doi.org/10.1177/17588359211039930
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1177/17588359211039930

Dieses zitieren

Müller, M., Posch, F., Kiem, D., Barth, D., Horvath, L., Stotz, M., Schaberl-Moser, R., Pichler, M., Greil, R., Jost, P. J., Seeber, A., Amann, A., Schlick, K., Gerger, A., & Riedl, J. M. (2021). Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 13, 17588359211039930. https://doi.org/10.1177/17588359211039930

@article{1acbcfe345b2473a8648bf9c918d9fb4,

title = "Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.",

keywords = "PHASE-II, 1ST-LINE TREATMENT, CANCER, CHEMOTHERAPY, DOCETAXEL, RECURRENT, PLATINUM, CAPECITABINE, FLUOROURACIL, PACLITAXEL",

author = "Moritz M{\"u}ller and Florian Posch and Dominik Kiem and Dominik Barth and Lena Horvath and Michael Stotz and Renate Schaberl-Moser and Martin Pichler and Richard Greil and Jost, {Philipp J} and Andreas Seeber and Arno Amann and Konstantin Schlick and Armin Gerger and Riedl, {Jakob M}",

note = "Greil; Schlick; Kiem: IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria",

year = "2021",

doi = "10.1177/17588359211039930",

language = "English",

volume = "13",

pages = "17588359211039930",

journal = "THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY",

issn = "1758-8340",

}

Müller, M, Posch, F, Kiem, D, Barth, D, Horvath, L, Stotz, M, Schaberl-Moser, R, Pichler, M, Greil, R, Jost, PJ, Seeber, A, Amann, A, Schlick, K, Gerger, A & Riedl, JM 2021, 'Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.', THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Jg. 13, S. 17588359211039930. https://doi.org/10.1177/17588359211039930

TY - JOUR

T1 - Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

AU - Müller, Moritz

AU - Posch, Florian

AU - Kiem, Dominik

AU - Barth, Dominik

AU - Horvath, Lena

AU - Stotz, Michael

AU - Schaberl-Moser, Renate

AU - Pichler, Martin

AU - Greil, Richard

AU - Jost, Philipp J

AU - Seeber, Andreas

AU - Amann, Arno

AU - Schlick, Konstantin

AU - Gerger, Armin

AU - Riedl, Jakob M

N1 - Greil; Schlick; Kiem: IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria

PY - 2021

Y1 - 2021

KW - PHASE-II

KW - 1ST-LINE TREATMENT

KW - CANCER

KW - CHEMOTHERAPY

KW - DOCETAXEL

KW - RECURRENT

KW - PLATINUM

KW - CAPECITABINE

KW - FLUOROURACIL

KW - PACLITAXEL

U2 - 10.1177/17588359211039930

DO - 10.1177/17588359211039930

M3 - Original Article (Journal)

C2 - 34616490

SN - 1758-8340

VL - 13

SP - 17588359211039930

JO - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

JF - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

ER -